Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delamanid for MDR-TB in China
NCT04421495Phase 4Unknown
- Sponsor
- Beijing Chest Hospital
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of delamanid in multidrug-resistant tuberculosis (MDR-TB), sponsored by Beijing Chest Hospital. Status: unknown.
02
Drugs
delamanid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT04421495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421495.